Bio Business

» biobusiness, drug development and biotech

Most Recent

image: Lazarus Drugs

Lazarus Drugs

By Kate Yandell | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Cannabis Biotech

Cannabis Biotech

By Daniel Cossins | December 1, 2014

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.


image: That Loving Feeling

That Loving Feeling

By Megan Scudellari | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Incubator Boom

Incubator Boom

By Kerry Grens | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  


image: Penetrating the Brain

Penetrating the Brain

By Megan Scudellari | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.


image: Remaking a Classic

Remaking a Classic

By Megan Scudellari | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.


image: Tumor Snipers

Tumor Snipers

By Megan Scudellari | November 1, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.


image: The Little Cell That Could

The Little Cell That Could

By Megan Scudellari | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Treating Fat with Fat

Treating Fat with Fat

By Edyta Zielinska | May 1, 2012

Is brown fat ready for therapeutic prime time?


image: Braving the IPO Drought

Braving the IPO Drought

By Megan Scudellari | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.


Popular Now

  1. Could Rapamycin Help Humans Live Longer?
  2. Elena Rybak-Akimova, Chemical Kinetics Expert, Dies
  3. University of Oregon Erecting a $1-Billion Science Center
  4. <em>Homo Sapiens</em> Interbred With Denisovans From Two Different Populations